Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:10 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers
NCT03345784 · National Cancer Institute (NCI) · PHASE1 · terminated · last registry update 2024-02-20 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Inadequate accrual rate” | – | Registry record, National Cancer Institute (NCI) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against WEE1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-10-01Results posted on the registry: National Cancer Institute (NCI), Adavosertib + Olaparib (NCT04197713)
- 2024-01-10Results posted on the registry: H. Lee Moffitt Cancer Center and Research Institute, Carboplatin + Paclitaxel (NCT02513563)
- 2024-01-03Results posted on the registry: National Cancer Institute (NCI), Adavosertib (NCT01922076)
- 2023-09-21Also stopped (terminated): Merck Sharp & Dohme LLC, adavosertib 20 mg + 5-FU 1000 mg/m^2/day (NCT01047007)
- 2023-09-18Also stopped (terminated): Merck Sharp & Dohme LLC, adavosertib + Topotecan (NCT01076400)
- 2023-09-13Results posted on the registry: National Cancer Institute (NCI), Adavosertib (NCT03253679)
- 2023-09-08Results posted on the registry: National Cancer Institute (NCI), Adavosertib + Gemcitabine Hydrochloride (NCT02101775)
- 2023-08-14Results posted on the registry: AstraZeneca, Adavosertib (NCT04590248)
- 2023-04-25Results posted on the registry: National Cancer Institute (NCI), AZD1775 + Gemcitabine (NCT02194829)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision